ENTREPRENEURS-ORG
Entrepreneurs’ Organization (EO) supported technology entrepreneurs from around the world at the Web Summit conference. EO members donated their time to provide two masterclasses, two mentoring sessions and judged a live start-up pitching competition. Interested entrepreneurs were able to visit the EO booth to find more information on resources and programmes offered.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211105005353/en/
Key EO contributions included:
- Mountaineer Saahil Mehta delivered a masterclass on how individuals can reinvent themselves to reach their own summits
- CEO Coach Eric Partaker delivered a masterclass on supercharging your productivity and achieving your full potential
- Private equity and venture capital investor Pavel Erochkine led mentoring hours for aspiring business leaders
- Author and marketer Nir Zavaro judged a start-up competition showcasing the world’s most promising early-stage start-ups
EO members leading the way in tech
More than 1,800 EO members – over 10% of its 15,000+ global membership – are in the technology industry globally. Of these, 170 are under 35.
EO supports the global tech entrepreneurship community by providing advice, mentorship and a support system to entrepreneurs in over 60 countries. Technology has played a crucial role in the survival and success of entrepreneurs around the world, and the opportunities it unlocked have supported businesses and led to growth and achievements for many business leaders in the last few years. Tech entrepreneurs have proven to be growth-oriented even during a global pandemic and have demonstrated the potential of technology for success.
EO at Web Summit
A delegation of nine EO members attended the summit, which took place at the Altice Arena & Fil in Lisbon from Monday 1 November until Thursday 4 November. They talked about their own experiences, the future of business and the lessons learned from the pandemic.
Experts from every industry came together for Web Summit to share ideas, network and discover the latest trends and opportunities. With a range of educational content, informative masterclasses and innovative roundtables, attendees gained valuable knowledge that will help them upskill and grow.
- ENDS –
Notes to editors
The Entrepreneurs’ Organization (EO) is a high-quality support network of 15,000+ like-minded leaders across 61 countries. EO helps entrepreneurs achieve their full potential through the power of life-enhancing connections, shared experiences, and collaborative learning. EO has been helping entrepreneurs achieve transformational growth since 1987 and its member network is committed to learning and helping each other succeed.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211105005353/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alpega Group Completes Leadership Succession Plan Appointing Daniel Cohen New CEO8.1.2026 10:03:00 CET | Press release
Alpega Group, a leading pan-European provider of an end-to-end transportation and logistics platform, today announced a planned leadership transition. After a successful tenure as Chief Executive Officer, Todd DeLaughter will be retiring, stepping down from his role and transitioning to a Board Advisor role for the company. The Board of Directors has appointed Daniel Cohen as the incoming CEO, effective January 1st, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260108528648/en/ Daniel Cohen, CEO Alpega Daniel Cohen brings three decades of experience leading B2B SaaS businesses through periods of change, scale, and value realization. Most recently, as CEO of PayU, he led a full financial, operational, and cultural transformation returning the business to sustained profitable growth. He subsequently steered the company through a highly complex, multi-jurisdictional process that culminated in the successful sale to Rapyd
FPT Named Sitecore’s First Global Partner Under Global Elite Reseller Program8.1.2026 09:00:00 CET | Press release
Global IT Corporation FPT announced its appointment as the inaugural Global Elite Reseller under a new initiative from Sitecore that expands upon its successful Global Reseller Program. The Global Elite Reseller Program follows the launch of SitecoreAI, the next-generation digital experience platform that puts artificial intelligence at the center of marketing, unifying content, data, and personalization in one composable platform so organizations can reach, engage, and serve their audience across digital channels. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107425261/en/ Representatives from FPT and Sitecore at the Global Elite Reseller signing ceremony. Under the agreement, FPT will hold exclusive reseller rights in Vietnam and non-exclusive rights across select markets in Asia and the Middle East, taking SitecoreAI to market and showing how it helps teams plan, create, and optimize digital experiences using AI as cu
Natus Sensory Appoints Arne Boye Nielsen to Board of Directors8.1.2026 08:00:00 CET | Press release
Natus Sensory, a global leader in sensory and diagnostic solutions, today announced the appointment of Arne Boye Nielsen to its Board of Directors, effective January 1, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107392331/en/ Arne Boye Nielsen Arne brings more than 30 years of executive leadership experience in diagnostics and medical technology, most notably as President of Demant Diagnostics, where he built and scaled the business into a global leader over three decades. During his tenure, Arne played a central role in shaping Demant Diagnostics’ long-term strategy, portfolio expansion, and international growth, establishing it as a cornerstone of Demant’s global healthcare footprint. In addition to his executive leadership background, Arne brings extensive board experience. His deep expertise across diagnostics, governance, and value creation will further strengthen Natus Sensory’s Board as the company contin
4Moving Biotech Receives FDA IND Clearance for 4P004, Strengthening Its Position as a Leading Innovator in Disease-Modifying Osteoarthritis Therapeutics8.1.2026 07:30:00 CET | Press release
FDA IND clearance enabling the worldwide expansion of the INFLAM MOTION Phase 2a trial, involving major U.S. sites Advancing the first clinical proof of concept in OA with a first-in-class intra-articular GLP-1 agonist A holistic clinical strategy design establishing the foundation for a future accelerated approval pathway 4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for 4P004, enabling the expansion of the Phase 2a INFLAM MOTION clinical trial into the United States (US). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107798042/en/ 4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. F
Organon Enters into a Commercialization Agreement for Daiichi Sankyo’s Nilemdo®in France, Denmark, Iceland, Sweden, Finland and Norway8.1.2026 07:30:00 CET | Press release
The agreement builds on Organon’s cardiovascular disease portfolio, leveraging expertise to expand access to new treatments for patients with dyslipidemia, especially statin-intolerant patients.This collaboration addresses a critical gap in care that disproportionately affects women, who are at a 47% higher risk of developing statin intolerance compared to men.i Organon today announced that it has entered into an agreement with Daiichi Sankyo Europe to commercialize Nilemdo® (bempedoic acid) in France, Denmark, Iceland, Sweden, Finland and Norway. Nilemdo® is a new, first-in-class drug indicated for patients with high cholesterol and cardiovascular disease risk. It provides an alternative treatment for patients that cannot be treated effectively with statins.ii “This collaboration combines Organon’s commercial agility with Daiichi Sankyo’s expertise in cardiovascular innovation to bring Nilemdo® to patients in France, Denmark, Iceland, Sweden, Finland and Norway,” says Thibault Crosnie
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom